(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 14.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.52%.
Niagen Bioscience's revenue in 2026 is $129,084,000.On average, 8 Wall Street analysts forecast NAGE's revenue for 2026 to be $11,385,440,428, with the lowest NAGE revenue forecast at $10,526,923,306, and the highest NAGE revenue forecast at $12,016,074,664. On average, 7 Wall Street analysts forecast NAGE's revenue for 2027 to be $13,159,445,393, with the lowest NAGE revenue forecast at $11,778,696,658, and the highest NAGE revenue forecast at $14,448,407,965.
In 2028, NAGE is forecast to generate $15,382,094,789 in revenue, with the lowest revenue forecast at $13,174,479,333 and the highest revenue forecast at $17,505,836,682.